Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
19.37
Nov 17 • 3:59 PM ET Dollar change+0.01 Percentage change(0.05%)
Aftermarket Close
19.37
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
931.07M
Enterprise Value
628.55M
Income
-151.97M
Sales
4.73M
Book/sh
7.84
Cash/sh
6.78
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
May 08, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
196.84
P/B
2.47
P/C
2.86
P/FCF
-
EV/EBITDA
-
EV/Sales
132.89
Quick Ratio
12.94
Current Ratio
12.94
Debt/Eq
0.06
LT Debt/Eq
0.05
Option/Short
No / Yes
EPS (ttm)
-3.18
EPS next Y
-4.44
EPS next Q
-1.09
EPS this Y
-13.86%
EPS next Y
24.42%
EPS next 5Y
6.00%
EPS past 3/5Y
-6.04% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-28.92%
Sales Q/Q
-100.00%
Insider Own
59.13%
Insider Trans
0.00%
Inst Own
37.22%
Inst Trans
45.91%
ROA
-
ROE
-
ROIC
-38.37%
Gross Margin
-6.68%
Oper. Margin
-3398.82%
Profit Margin
-3212.18%
SMA20
-1.23%
SMA50
-4.58%
SMA200
-1.76%
Trades
Shs Outstand
47.94M
Shs Float
19.65M
52W High
29.05 -33.32%
52W Low
15.10 28.28%
Volatility
8.88% 9.25%
ATR (14)
1.65
RSI (14)
48.05
Beta
-
Rel Volume
0.97
Avg Volume
309.87K
Volume
301,619
Perf Week
-3.15%
Perf Month
7.02%
Perf Quarter
-20.12%
Perf Half Y
14.34%
Perf YTD
-3.15%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
19.36
Price
19.37
Change %
0.05%
Consensus
Strong Buy
Avg. Price Target
$34.67
Implied Upside
+79.0%
Analysts8incl. previous ratings
Rating Distribution8 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 06, 2026Resumed
HH.C. Wainwright
Buy$40+106.5%
Oct 12, 2026Initiated
UBS logoUUBS
Buy$27+39.4%
Oct 09, 2026Initiated
RJF logoRRaymond James
Outperform$42+116.8%
Aug 27, 2026Initiated
HH.C. Wainwright
Buy$44+127.2%
Jun 02, 2026Initiated
WWedbush
Outperform$30+54.9%
Jun 02, 2026Initiated
TD logoTTD Cowen
Buy
Jun 02, 2026Initiated
OPY logoOOppenheimer
Outperform$40+106.5%
Jun 02, 2026Initiated
JPM logoJJP Morgan
Overweight$26+34.2%
Jun 02, 2026Initiated
CCantor Fitzgerald
Overweight
Nov-10-26 08:00AM
Nov-04-26 07:39AM
07:00AM
Oct-20-26 07:00AM
Oct-12-26 08:00AM
08:00AM Loading…
Oct-06-26 08:00AM
Sep-16-26 08:00AM
Aug-26-26 08:00AM
Aug-07-26 06:10AM
Aug-06-26 06:32AM
Aug-04-26 07:00AM
Jun-18-26 12:56PM
Jun-17-26 04:51PM
04:15PM
May-11-26 08:31AM
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TPG GP A, LLCFormer 10% OwnerMay 11 '26Buy18.001,388,88925,000,0023,690,146May 13 05:10 PM
Dimension Capital II, L.P.DirectorMay 08 '26Buy18.001,111,11119,999,9983,333,516May 12 05:37 PM
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerMay 11 '26Buy18.00555,5559,999,9901,831,383May 11 09:11 PM
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerMay 11 '26Sale18.001,78032,040440,981May 11 09:11 PM
LEIDEN JEFFREY MDirectorMay 08 '26Buy20.005,000100,000270,198May 11 08:35 PM
Haas JasonChief Financial OfficerMay 08 '26Buy20.001,00020,00062,908May 11 08:32 PM
Li Nan (LN)DirectorMay 11 '26Buy18.001,111,11119,999,9983,333,516May 11 08:30 PM
Chu ShelleyDirectorMay 11 '26Buy18.0011,111199,99811,111May 11 08:30 PM
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.
FounderDr. Gary D. Glick Ph.D.
Chief Financial OfficerMr. Jason Haas M.B.A.
Senior Vice President of Strategy & Business DevelopmentMr. Collin Todd
Ph.D.Prof. Eicke Latz M.D.
Scientific Co-FounderDr. Kim Lewis Ph.D.